Assembly Biosciences Unveils Interim Phase 1b Results for HSV Helicase-Primase Inhibitor ABI-5366 at the 38th IUSTI Europe Congress on Sexually Transmitted Infections
Interim Phase 1b Data Presentation: Assembly Biosciences presented interim Phase 1b data for its HSV helicase-primase inhibitor ABI-5366, showing significant reductions in HSV-2 shedding and genital lesions in participants receiving a 350 mg weekly dose compared to placebo.
Future Studies and Collaborations: The company plans to share additional data on ABI-5366 and another candidate, ABI-1179, later this fall, with Phase 2 studies for ABI-5366 expected to begin in mid-2026, under a collaboration agreement with Gilead Sciences.
Trade with 70% Backtested Accuracy
Analyst Views on ASMB
About ASMB
About the author
Gilead Licenses Assembly Bio's HSV Programs, Secures $35 Million Investment
- Exclusive Licensing Agreement: Gilead Sciences has exercised its option to exclusively license Assembly Bio's HSV inhibitor programs, including ABI-1179 and ABI-5366, marking the first advancement under their R&D collaboration and potentially benefiting over four million patients.
- Positive Clinical Data: Interim Phase 1b data for ABI-5366 and ABI-1179 demonstrated antiviral activity with a significant reduction in virus-positive lesions, indicating promising clinical prospects for treating recurrent genital herpes.
- Clear Financial Terms: Under the 2023 collaboration agreement, Assembly Bio will receive a $35 million upfront payment and is eligible for up to $330 million in regulatory and commercial milestone payments, reflecting Gilead's commitment to the project's future potential.
- Significant Market Opportunity: Given that no new therapies have been approved for HSV in over 25 years, Gilead's initiative not only fills a market gap but also enhances its competitive position in the antiviral drug market by improving patient quality of life.
Gilead Secures Exclusive License for Assembly Bio's HSV Programs, Receives $35M Payment
- Exclusive Licensing Agreement: Gilead Sciences has exercised its option to exclusively license Assembly Biosciences' HSV programs, gaining rights to clinical development and commercialization of ABI-1179 and ABI-5366, marking a strategic expansion in the antiviral sector.
- Financial Injection: Assembly Bio will receive a $35 million payment from Gilead's exercise of the license, which not only strengthens its financial position but also provides funding for future research and development efforts.
- Potential Earnings: Assembly Bio remains eligible for up to $330 million in regulatory and commercial milestone payments, along with tiered royalties on net sales, significantly enhancing its future revenue potential.
- Market Impact: Gilead's acquisition bolsters its market position in reproductive health, with expectations to accelerate the clinical development of related products, thereby securing a more advantageous stance in the competitive antiviral drug market.
Gilead Activates License for Assembly Biosciences' Herpes Initiatives
Gilead Sciences Licenses Assembly Biosciences: Gilead Sciences has licensed Assembly Biosciences' herpes simplex virus helicase-primase inhibitor programs for recurrent genital herpes, covering phase 1 candidates ABI-1179 and ABI-5366.
Financial Terms of the Deal: The agreement includes an $84.8 million upfront payment, a $15.2 million equity investment, and potential milestone payments of approximately $330 million per program, as part of a 12-year partnership established in October 2023.
Assembly Software Reports 350% Year-over-Year Growth in NeosAI Adoption for 2025
- User Engagement Surge: In 2025, NeosAI adoption surged by 350% year-over-year, reflecting not only increased customer trust in legal AI but also a pressing demand for efficient workflows among legal teams.
- Significant Time Savings: NeosAI enabled legal teams to save over 500,000 hours of work, allowing the company to focus more on client service, thereby enhancing overall business efficiency.
- Transaction Volume Spike: Monthly transaction volume increased by 765% year-over-year, showcasing NeosAI's broad application potential in the legal industry and potentially leading to substantial revenue growth for Assembly.
- Enhanced Industry Recognition: NeosAI was awarded the 2025 LegalTech Generative AI Solution of the Year, further solidifying Assembly's leadership in the legal tech space, boosting customer confidence, and driving market share growth.
Assembly Unveils Encouraging Initial Trial Findings for ABI-1179 and ABI-5366 in Recurrent Genital Herpes
Positive Interim Results: Assembly Biosciences reported promising interim results from Phase 1b trials of its oral drugs ABI-1179 and ABI-5366 for recurrent genital herpes, showing significant reductions in HSV-2 shedding and genital lesions compared to placebo.
ABI-1179 Findings: The 50 mg weekly dose of ABI-1179 demonstrated a 98% reduction in HSV-2 shedding and a 91% reduction in genital lesions, with the drug being well-tolerated and supporting once-weekly dosing.
ABI-5366 Findings: The monthly dosing of ABI-5366 showed a 76% reduction in HSV-2 shedding and an 88% reduction in genital lesions, with positive results from earlier weekly dosing cohorts as well.
Future Plans: Assembly Biosciences plans to initiate Phase 2 clinical trials for ABI-5366, focusing on a once-weekly regimen, around mid-2026.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
Gilead Licenses Assembly Bio's HSV Programs, Secures $35 Million Investment
- Exclusive Licensing Agreement: Gilead Sciences has exercised its option to exclusively license Assembly Bio's HSV inhibitor programs, including ABI-1179 and ABI-5366, marking the first advancement under their R&D collaboration and potentially benefiting over four million patients.
- Positive Clinical Data: Interim Phase 1b data for ABI-5366 and ABI-1179 demonstrated antiviral activity with a significant reduction in virus-positive lesions, indicating promising clinical prospects for treating recurrent genital herpes.
- Clear Financial Terms: Under the 2023 collaboration agreement, Assembly Bio will receive a $35 million upfront payment and is eligible for up to $330 million in regulatory and commercial milestone payments, reflecting Gilead's commitment to the project's future potential.
- Significant Market Opportunity: Given that no new therapies have been approved for HSV in over 25 years, Gilead's initiative not only fills a market gap but also enhances its competitive position in the antiviral drug market by improving patient quality of life.
Gilead Secures Exclusive License for Assembly Bio's HSV Programs, Receives $35M Payment
- Exclusive Licensing Agreement: Gilead Sciences has exercised its option to exclusively license Assembly Biosciences' HSV programs, gaining rights to clinical development and commercialization of ABI-1179 and ABI-5366, marking a strategic expansion in the antiviral sector.
- Financial Injection: Assembly Bio will receive a $35 million payment from Gilead's exercise of the license, which not only strengthens its financial position but also provides funding for future research and development efforts.
- Potential Earnings: Assembly Bio remains eligible for up to $330 million in regulatory and commercial milestone payments, along with tiered royalties on net sales, significantly enhancing its future revenue potential.
- Market Impact: Gilead's acquisition bolsters its market position in reproductive health, with expectations to accelerate the clinical development of related products, thereby securing a more advantageous stance in the competitive antiviral drug market.
Gilead Activates License for Assembly Biosciences' Herpes Initiatives
Gilead Sciences Licenses Assembly Biosciences: Gilead Sciences has licensed Assembly Biosciences' herpes simplex virus helicase-primase inhibitor programs for recurrent genital herpes, covering phase 1 candidates ABI-1179 and ABI-5366.
Financial Terms of the Deal: The agreement includes an $84.8 million upfront payment, a $15.2 million equity investment, and potential milestone payments of approximately $330 million per program, as part of a 12-year partnership established in October 2023.
Assembly Software Reports 350% Year-over-Year Growth in NeosAI Adoption for 2025
- User Engagement Surge: In 2025, NeosAI adoption surged by 350% year-over-year, reflecting not only increased customer trust in legal AI but also a pressing demand for efficient workflows among legal teams.
- Significant Time Savings: NeosAI enabled legal teams to save over 500,000 hours of work, allowing the company to focus more on client service, thereby enhancing overall business efficiency.
- Transaction Volume Spike: Monthly transaction volume increased by 765% year-over-year, showcasing NeosAI's broad application potential in the legal industry and potentially leading to substantial revenue growth for Assembly.
- Enhanced Industry Recognition: NeosAI was awarded the 2025 LegalTech Generative AI Solution of the Year, further solidifying Assembly's leadership in the legal tech space, boosting customer confidence, and driving market share growth.
Assembly Unveils Encouraging Initial Trial Findings for ABI-1179 and ABI-5366 in Recurrent Genital Herpes
Positive Interim Results: Assembly Biosciences reported promising interim results from Phase 1b trials of its oral drugs ABI-1179 and ABI-5366 for recurrent genital herpes, showing significant reductions in HSV-2 shedding and genital lesions compared to placebo.
ABI-1179 Findings: The 50 mg weekly dose of ABI-1179 demonstrated a 98% reduction in HSV-2 shedding and a 91% reduction in genital lesions, with the drug being well-tolerated and supporting once-weekly dosing.
ABI-5366 Findings: The monthly dosing of ABI-5366 showed a 76% reduction in HSV-2 shedding and an 88% reduction in genital lesions, with positive results from earlier weekly dosing cohorts as well.
Future Plans: Assembly Biosciences plans to initiate Phase 2 clinical trials for ABI-5366, focusing on a once-weekly regimen, around mid-2026.
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Exicure, Inc. Surge: Exicure, Inc. saw a significant after-hours increase of 72.61% to $9.20 following positive Phase 2 trial results for its therapy in multiple myeloma patients, with 90% of participants achieving the primary endpoint.
Artiva Biotherapeutics and iBio Performance: Artiva Biotherapeutics rose 10.39% after hours despite a regular session decline, while iBio advanced 8.38% after hours, continuing its earlier gains without any new announcements.
Cartesian Therapeutics and Metagenomi Gains: Cartesian Therapeutics increased 6.55% after hours, while Metagenomi gained 7.18% after hours, with the latter planning to present preclinical data at an upcoming conference.
Wave Life Sciences and Assembly Biosciences Updates: Wave Life Sciences shares rose 4.97% after hours following a public offering announcement, and Assembly Biosciences gained 5.96% after reporting positive interim results from Phase 1b studies of its investigational HSV inhibitors.
